Charts: Biotech bull market intact, buy this ETF

A trader works on the floor of the New York Stock Exchange.
Getty Images
A trader works on the floor of the New York Stock Exchange.

Despite some recent talk of a biotech bubble, asset prices are always the final arbiter because they show supply and demand as indicated by investors with real money in the game and— at least according to one biotech sector exchange-traded fund—there is still more upside potential in this trade.

Here's why.